Research progress on recombinant NDV in cancer therapy

Area of Science:

• Oncology
• Virology
• Immunotherapy

Background:

• Newcastle disease virus (NDV) exhibits oncolytic properties, directly lysing tumor cells and stimulating immune responses.
• Wild-type NDV efficacy is often limited and inconsistent in cancer treatment.
• Genetic engineering has produced recombinant NDVs (rNDVs) with improved safety and efficacy.

Purpose of the Study:

• To review the current advancements in recombinant Newcastle disease viruses (rNDVs) for cancer therapy.
• To summarize modification strategies, antitumor mechanisms, and clinical applications of rNDVs.
• To discuss challenges and future directions for rNDV utilization in oncology.

Main Methods:

• Review of existing literature on NDV and rNDV research in cancer therapy.
• Analysis of genetic engineering strategies for NDV modification.
• Evaluation of antitumor mechanisms, including direct lysis and immune activation.
• Assessment of clinical applications, combination therapies, and challenges.

Main Results:

• rNDVs demonstrate enhanced direct tumor cell lysis and potentiation of innate and adaptive immune responses.
• Genetically engineered rNDVs optimize the tumor microenvironment by increasing pro-inflammatory cytokine secretion.
• rNDVs induce systemic antitumor immunity, improving overall therapeutic outcomes.
• Various modification strategies have been employed to enhance rNDV oncolytic activity and safety.

Conclusions:

• rNDVs represent a promising next-generation oncolytic virus therapy for cancer.
• Further research is needed to overcome challenges such as delivery routes, antibody evasion, tumor heterogeneity, and biomarker identification.
• rNDVs hold significant potential for improving cancer treatment through enhanced antitumor activity and immune modulation.